At the "China Pharmaceutical Innovation and Investment Conference", after the release of the Phase I clinical data (including the involved tumor spectrum and treatment trends) of the CHA injection developed by Jiuzhang Biotech, Nature magazine conducted exclusive interviews with Mr. Zhang Jie, the inventor, Professor Chen Xiaoguang from the Institute of Materia Medica of the Chinese Academy of Medical Sciences who is in charge of the research on the anti-tumor mechanism, and Professor Li Wenbin from the Department of Glioma at Beijing Shijitan Hospital who is the main person in charge of the glioma clinical trial.

[Patient Recruitment] Phase I Clinical Trial on the Safety, Tolerability and Pharmacokinetics of CHA for Injection in the Treatment of Advanced Malignant Gliomas

For a long time, the employees of our company have raised cash through spontaneous donations and established a student - aid fund. We support some children who are excellent in both character and learning but from poor families to continue their studies and complete their education. On November 25, 2015, we delivered necessities such as winter clothes and school supplies we purchased to Huatou Primary School in Jiajiang County, Leshan City, to help these children from poor families tide over difficulties. We provide each poor student with a living allowance of 100 yuan per month (except for one student who, due to extremely difficult family circumstances, is given 200 yuan per month) to help these children improve their living conditions. We hope that through their hard - working and diligent studies, they will be able to contribute to the country and benefit society in the future.

Without the permission of our company, Shanghu.com has unauthorizedly used the relevant information of Sichuan Jiuzhang Biotechnology Co., Ltd. (including the company's introduction, contact information, address, product information, etc.) to carry out the sales promotion of chlorogenic acid bulk drugs. After our company discovered and verified this situation, we immediately notified Shanghu.com to delete the relevant information. However, up to now, Shanghu.com has still not deleted the relevant information. In order to prevent our numerous customers and relevant cooperative units of Jiuzhang Biology from suffering economic losses due to this, we hereby issue this information announcement. Our company will continue to negotiate with Shanghu.com to safeguard our legitimate rights and interests.

On December 10, 2014, Sichuan Jiuzhang Biotechnology Co., Ltd. and the Institute of Materia Medica, Chinese Academy of Medical Sciences jointly initiated the establishment of the CHA Research and Development Cooperative Committee. Based on the potentially huge scientific value of CHA in scientific and technological and clinical application aspects, the committee will, from a comprehensive perspective, plan and guide the research direction of the CHA project, standardize and supervise the information dissemination and information security during the research and development process of CHA. By gathering innovative elements, activating innovative resources, transforming innovative achievements, etc., it aims to achieve the sustainable development of CHA-related research.

On December 10, 2014, the "Research and Development Seminar on CHA Injection, a Class 1.2 Antitumor New Drug" was organized by the Institute of Materia Medica, Chinese Academy of Medical Sciences and held in Beijing. The participating experts and leaders are as follows: